Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
ITIC
3626
Investors Title Co
ITIC
$548M
| $694K | ﹤0.01% |
2,778
+214
| +8% | +$56.2K |
2017 Q3
33 quarters
|
|
3627
Mayville Engineering Co
MEC
$419M
| $693K | ﹤0.01% |
37,025
+348
| +0.9% | +$5.67K |
2019 Q2
26 quarters
|
|
3628
Imperial Oil
IMO
$60.8B
| $692K | ﹤0.01% |
8,023
+4,578
| +133% | +$417K |
2013 Q2
50 quarters
|
|
3629
Entrada Therapeutics
TRDA
$209M
| $690K | ﹤0.01% |
67,147
+6,517
| +11% | +$54.9K |
2022 Q1
15 quarters
|
|
3630
Xponential Fitness
XPOF
$198M
| $690K | ﹤0.01% |
83,829
+3,524
| +4% | +$25K |
2022 Q1
15 quarters
|
|
3631
Frequency Electronics
FEIM
$970M
| $689K | ﹤0.01% |
12,796
+2,808
| +28% | +$103K |
2024 Q3
5 quarters
|
|
3632
Bioventus
BVS
$897M
| $688K | ﹤0.01% |
92,523
+26,547
| +40% | +$191K |
2023 Q3
9 quarters
|
|
3633
Ennis
EBF
$571M
| $687K | ﹤0.01% |
38,164
+3,191
| +9% | +$55.6K |
2016 Q3
37 quarters
|
|
3634
Carter Bankshares
CARE
$712M
| $686K | ﹤0.01% |
34,902
+2,625
| +8% | +$48.9K |
2022 Q1
15 quarters
|
|
|
CWAN
3635
CALL
DELISTED
Clearwater Analytics
CWAN
| $685K | ﹤0.01% |
+28,400
| New | +$569K |
2025 Q4
0 quarters
|
|
3636
Vanguard Russell 1000 Growth ETF
VONG
$47.5B
| $682K | ﹤0.01% |
+5,600
| New | +$683K |
2025 Q4
0 quarters
|
|
|
CTNM
3637
Contineum Therapeutics
CTNM
$494M
| $680K | ﹤0.01% |
59,507
+53,031
| +819% | +$605K |
2024 Q2
6 quarters
|
|
3638
Anika Therapeutics
ANIK
$256M
| $678K | ﹤0.01% |
70,506
+38,432
| +120% | +$368K |
2013 Q2
50 quarters
|
|
|
UBFO
3639
DELISTED
United Security Bancshares
UBFO
| $677K | ﹤0.01% |
67,255
+16,005
| +31% | +$154K |
2017 Q2
34 quarters
|
|
|
OLP
3640
One Liberty Properties
OLP
$482M
| $677K | ﹤0.01% |
33,364
+4,995
| +18% | +$103K |
2013 Q2
50 quarters
|
|
3641
Lesaka Technologies
LSAK
$372M
| $677K | ﹤0.01% |
141,866
+140,812
| +13,360% | +$586K |
2023 Q1
11 quarters
|
|
|
FLOC
3642
Flowco Holdings
FLOC
$812M
| $674K | ﹤0.01% |
35,983
+6,095
| +20% | +$102K |
2025 Q1
3 quarters
|
|
3643
Viant Technology
DSP
$259M
| $674K | ﹤0.01% |
55,975
+6,801
| +14% | +$68K |
2022 Q1
15 quarters
|
|
|
LBRX
3644
LB Pharmaceuticals
LBRX
$1.19B
| $673K | ﹤0.01% |
30,215
-624
| -2% | -$10.9K |
2025 Q3
1 quarter
|
|
|
XRN
3645
Chiron Real Estate Inc
XRN
$450M
| $672K | ﹤0.01% |
19,911
+2,891
| +17% | +$94.3K |
2017 Q1
35 quarters
|
|
|
BLTE
3646
Belite Bio
BLTE
$6.43B
| $668K | ﹤0.01% |
+4,176
| New | +$495K |
2025 Q4
0 quarters
|
|
3647
Atlanticus Holdings
ATLC
$1.39B
| $666K | ﹤0.01% |
9,949
+1,054
| +12% | +$62K |
2020 Q2
22 quarters
|
|
3648
PUT
Riot Platforms
RIOT
$7.4B
| $665K | ﹤0.01% |
52,500
-226,900
| -81% | -$3.88M |
2024 Q4
4 quarters
|
|
3649
MoonLake Immunotherapeutics
MLTX
$971M
| $662K | ﹤0.01% |
50,251
+50,235
| +313,969% | +$593K |
2023 Q3
9 quarters
|
|
3650
U-Haul Holding Co Series N
UHAL.B
$10.6B
| $661K | ﹤0.01% |
14,147
-33,491
| -70% | -$1.63M |
2022 Q4
12 quarters
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.